Can Nutraceuticals Prevent Alzheimer's Disease? Potential Therapeutic Role of a Formulation Containing Shilajit and Complex B Vitamins

Carrasco-Gallardo, Carlos; Farías, Gonzalo; Fuentes, Patricio; Crespo, Fernando; Maccioni, Ricardo B.

doi:10.1016/j.arcmed.2012.10.010

Cited by 47 publications

(27 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Andean Compound is a very complex mixture of humic substances generated by natural millenary decomposition of vegetal material and is originated as an endemic natural product from the Andes Mountains. Andean Compound and its major active principle—fulvic acid—emerge as novel nutraceutical with potential uses against neurodegenerative brain disorders (Carrasco-Gallardo et al, 2012a). This natural compound is a potent anti-inflammatory substance, and a very safe dietary supplement (Carrasco-Gallardo et al, 2012b).…”

Section: New Research Avenuesmentioning

confidence: 99%

Neuroinflammation in the pathogenesis of Alzheimerâ€™s disease. A rational framework for the search of novel therapeutic approaches

Morales¹,

Guzmán‐Martínez²,

Cerda-Troncoso³

et al. 2014

Front. Cell. Neurosci.

Self Cite

393

297

View full text Add to dashboard Cite

Alzheimer disease (AD) is the most common cause of dementia in people over 60 years old. The molecular and cellular alterations that trigger this disease are still diffuse, one of the reasons for the delay in finding an effective treatment. In the search for new targets to search for novel therapeutic avenues, clinical studies in patients who used anti-inflammatory drugs indicating a lower incidence of AD have been of value to support the neuroinflammatory hypothesis of the neurodegenerative processes and the role of innate immunity in this disease. Neuroinflammation appears to occur as a consequence of a series of damage signals, including trauma, infection, oxidative agents, redox iron, oligomers of τ and β-amyloid, etc. In this context, our theory of Neuroimmunomodulation focus on the link between neuronal damage and brain inflammatory process, mediated by the progressive activation of astrocytes and microglial cells with the consequent overproduction of proinflammatory agents. Here, we discuss about the role of microglial and astrocytic cells, the principal agents in neuroinflammation process, in the development of neurodegenerative diseases such as AD. In this context, we also evaluated the potential relevance of natural anti-inflammatory components, which include curcumin and the novel Andean Compound, as agents for AD prevention and as a coadjuvant for AD treatments.

show abstract

Section: New Research Avenuesmentioning

confidence: 99%

Neuroinflammation in the pathogenesis of Alzheimerâ€™s disease. A rational framework for the search of novel therapeutic approaches

Morales¹,

Guzmán‐Martínez²,

Cerda-Troncoso³

et al. 2014

Front. Cell. Neurosci.

Self Cite

393

297

View full text Add to dashboard Cite

show abstract

“…This natural endemic phytocomplex, resulting from fossilized plants degradation through the years, was discovered in 2008 in the North of Chile and was named Andean Compound (41). In vitro assays and cell culture data show that Andean Compound and FA strongly interferes with tau aggregation, and interestingly an increase in neurites outgrowth has been observed in neural cell cultures exposed to this natural compound (42). In addition, a placebo-controlled pilot clinical study suggests that consumption of a nutraceutical formulation of Andean Compound plus B complex vitamins may produce stabilization of cognitive function in AD patients at a 24-weeks as determined with Global deterioration scale (GDS) and Neuropsychiatric inventory (NPI) measurements (42) (Figure 2).…”

Section: Tau As a Therapeutic Target For Anti-alzheimer Drugsmentioning

confidence: 99%

Tau Oligomers as Potential Targets for Alzheimer’s Diagnosis and Novel Drugs

2013

Self Cite

View full text Add to dashboard Cite

A cumulative number of approaches have been carried out to elucidate the pathogenesis of Alzheimer’s disease (AD). Tangles formation has been identified as a major event involved in the neurodegenerative process, due to the conversion of either soluble peptides or oligomers into insoluble filaments. Most of recent studies share in common the observation that formation of tau oligomers and the subsequent pathological filaments arrays is a critical step in AD etiopathogenesis. Oligomeric tau species appear to be toxic for neuronal cells, and therefore appear as an appropriate target for the design of molecules that may control morphological and functional alterations leading to cognitive impairment. Thus, current therapeutic strategies are aimed at three major types of molecules: (1) inhibitors of protein kinases and phosphatases that modify tau and that may control neuronal degeneration, (2) methylene blue, and (3) natural phytocomplexes and polyphenolics compounds able to either inhibit the formation of tau filaments or disaggregate them. Only a few polyphenolic molecules have emerged to prevent tau aggregation. In this context, fulvic acid (FA), a humic substance, has potential protective activity cognitive impairment. In fact, formation of paired helical filaments in vitro, is inhibited by FA affecting the length of fibrils and their morphology.

show abstract

“…These studies and others suggest microglia as a promising therapeutic target for AD [36]. Another approach being investigated by researchers at the International Center for Biomedicine in Chile targets brain inflammation through the use of a nutraceutical that appears to protect neurons by disaggregating human pathological tau protein filaments [37,38].…”

Section: Developing Therapies For Admentioning

confidence: 96%